Movatterモバイル変換


[0]ホーム

URL:


PT3625263T - Anti-galectin-9 antibodies and uses thereof - Google Patents

Anti-galectin-9 antibodies and uses thereof

Info

Publication number
PT3625263T
PT3625263TPT188702708TPT18870270TPT3625263TPT 3625263 TPT3625263 TPT 3625263TPT 188702708 TPT188702708 TPT 188702708TPT 18870270 TPT18870270 TPT 18870270TPT 3625263 TPT3625263 TPT 3625263T
Authority
PT
Portugal
Prior art keywords
galectin
antibodies
Prior art date
Application number
PT188702708T
Other languages
Portuguese (pt)
Original Assignee
Pure Tech Lyt Inc
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=66246040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3625263(T)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pure Tech Lyt Inc, Univ New YorkfiledCriticalPure Tech Lyt Inc
Publication of PT3625263TpublicationCriticalpatent/PT3625263T/en

Links

Classifications

Landscapes

PT188702708T2017-10-272018-10-29Anti-galectin-9 antibodies and uses thereofPT3625263T (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US201762578111P2017-10-272017-10-27
US201862665175P2018-05-012018-05-01
US201862736317P2018-09-252018-09-25

Publications (1)

Publication NumberPublication Date
PT3625263Ttrue PT3625263T (en)2025-06-20

Family

ID=66246040

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PT188702708TPT3625263T (en)2017-10-272018-10-29Anti-galectin-9 antibodies and uses thereof

Country Status (14)

CountryLink
US (5)US10344091B2 (en)
EP (2)EP4597112A2 (en)
JP (5)JP6873445B2 (en)
KR (1)KR102162129B1 (en)
CN (2)CN111511765B (en)
AU (3)AU2018355588C1 (en)
CA (1)CA3080120C (en)
DK (1)DK3625263T3 (en)
ES (1)ES3032734T3 (en)
IL (3)IL312910A (en)
PT (1)PT3625263T (en)
SG (1)SG11202003652QA (en)
WO (1)WO2019084553A1 (en)
ZA (3)ZA202002246B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
PT3625263T (en)2017-10-272025-06-20Pure Tech Lyt IncAnti-galectin-9 antibodies and uses thereof
CN111256416B (en)*2018-11-302025-09-09海尔智家股份有限公司Air-cooled refrigerator
CA3134942A1 (en)*2019-03-252020-10-01New York UniversityAnti-galectin-9 antibodies and uses thereof
JP7581238B2 (en)*2019-05-012024-11-12ニューヨーク・ユニバーシティ Anti-galectin 9 antibodies and uses thereof
AU2020285369A1 (en)*2019-05-312021-12-23The Council Of The Queensland Institute Of Medical ResearchAnti-GAL9 immune-inhibiting binding molecules
WO2020243623A1 (en)*2019-05-312020-12-03The Council Of The Queensland Institute Of Medical ResearchActivating anti-gal9 binding molecules
WO2020260741A1 (en)*2019-06-242020-12-30Upm-Kymmene CorporationTransplantable cell composition comprising eukaryotic cells in a nanofibrillar cellulose hydrogel, method for preparing thereof and use of nanofibrillar cellulose
US20220242955A1 (en)*2019-07-112022-08-04Dana-Farber Cancer Institute, Inc.Targeting galectin-9 as a therapeutic strategy for t-cell exhaustion in t-cell acute lymphoblastic leukemia
US20220332832A1 (en)*2019-08-012022-10-20New York UniversityCombined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP2022544308A (en)*2019-08-142022-10-17モッドマブ セラピューティクス インコーポレイテッド Antibodies that bind to LRP5 protein and methods of use
CN115210261B (en)*2020-01-072025-07-18高诚生物医药公司Anti-galectin-9 antibodies and uses thereof
US20230295564A1 (en)*2020-07-232023-09-21Emory UniversityGalectin-9 Specific Binding Agents for Use in Treating Cancer
EP4192501A1 (en)*2020-08-042023-06-14Exelixis, Inc.Cd47 binding agents and uses thereof
WO2022031695A1 (en)*2020-08-042022-02-10Exelixis, Inc.Pd-l1 binding agents and uses thereof
CN116390939A (en)*2020-08-042023-07-04埃克塞里艾克西斯公司Multispecific binding agents and uses thereof
WO2022093841A1 (en)*2020-10-262022-05-05Puretech Lyt, Inc.Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
WO2022109302A1 (en)*2020-11-202022-05-27New York UniversityAnti-galectin-9 antibodies and therapeutic uses thereof
AU2022227029A1 (en)*2021-02-262023-08-31New York UniversityCompositions and methods comprising antibodies that bind to covalent peptide conjugates
IL308020A (en)*2021-04-302023-12-01Puretech Lyt IncCombination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
WO2022261337A2 (en)*2021-06-112022-12-15The Regents Of The University Of CaliforniaAntibodies that stimulate nk cell-mediated cytotoxicity
WO2023060192A2 (en)*2021-10-062023-04-13The University Of ChicagoSurvivin targeting polypeptides for detection and treatment of cancer
WO2023245021A2 (en)*2022-06-142023-12-21Invenra Inc.Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
AU2023301056A1 (en)*2022-06-292025-01-16Puretech Lyt, Inc.Treatment of hematological malignancies with antibodies inhibiting galectin-9
US20240277122A1 (en)*2023-02-162024-08-22Dongguan Casekey Industry Co., LtdCard fixation assembly for card holder and card holder
AR132931A1 (en)2023-06-122025-08-13Amgen Inc Lymphotoxin receptor agonist binding proteins b
WO2025014933A1 (en)*2023-07-102025-01-16Northwestern UniversityTargeting tim-3 in mapk-driven glioma
WO2025085792A1 (en)*2023-10-192025-04-24Puretech Lyt, Inc.Treatment of hematological malignancies with antibodies inhibiting galectin-9
WO2025129249A1 (en)*2023-12-222025-06-26Commonwealth Scientific And Industrial Research OrganisationIdentifying sequence functionality

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3773919A (en)1969-10-231973-11-20Du PontPolylactide-drug mixtures
US4485045A (en)1981-07-061984-11-27Research CorporationSynthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en)1983-06-201985-10-01Trustees University Of MassachusettsLiposomes containing modified cholesterol for organ targeting
US4777127A (en)1985-09-301988-10-11Labsystems OyHuman retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en)1986-01-231986-02-26Wilson R HNucleotide sequences
US4868103A (en)1986-02-191989-09-19Enzo Biochem, Inc.Analyte detection by means of energy transfer
US4704692A (en)1986-09-021987-11-03Ladner Robert CComputer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en)1987-09-211990-08-07Genex CorporationSingle polypeptide chain binding molecules
IL85035A0 (en)1987-01-081988-06-30Int Genetic EngPolynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en)1987-02-071987-03-11Al Sumidaie A M KObtaining retrovirus-containing fraction
US5219740A (en)1987-02-131993-06-15Fred Hutchinson Cancer Research CenterRetroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en)1988-05-301995-06-06Depotech CorporationHeterovesicular liposomes
AP129A (en)1988-06-031991-04-17Smithkline Biologicals S AExpression of retrovirus gag protein eukaryotic cells
US5223409A (en)1988-09-021993-06-29Protein Engineering Corp.Directed evolution of novel binding proteins
EP1541682A3 (en)1988-09-022005-07-06Dyax Corp.Generation and selection of recombinant varied binding proteins
EP0832980B1 (en)1989-01-232002-06-19Chiron CorporationRecombinant therapies for infection and hyperproliferative disorders
AU5344190A (en)1989-03-211990-10-22Vical, Inc.Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en)1989-03-211997-12-30Wisconsin Alumni Research FoundationGeneration of antibodies through lipid mediated DNA delivery
EP0845537A1 (en)1989-08-181998-06-03Chiron CorporationRecombinant retroviruses delivering vector constructs to target cells
US5585362A (en)1989-08-221996-12-17The Regents Of The University Of MichiganAdenovirus vectors for gene therapy
US5013556A (en)1989-10-201991-05-07Liposome Technology, Inc.Liposomes with enhanced circulation time
ZA911974B (en)1990-03-211994-08-22Res Dev FoundationHeterovesicular liposomes
US5427908A (en)1990-05-011995-06-27Affymax Technologies N.V.Recombinant library screening methods
GB9015198D0 (en)1990-07-101990-08-29Brien Caroline J OBinding substance
WO1992020791A1 (en)1990-07-101992-11-26Cambridge Antibody Technology LimitedMethods for producing members of specific binding pairs
ES2113940T3 (en)1990-12-031998-05-16Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
EP0575485A1 (en)1991-03-011993-12-29Dyax Corp.Process for the development of binding mini-proteins
DE69233750D1 (en)1991-04-102009-01-02Scripps Research Inst Libraries of heterodimeric receptors using phagemids
DE4122599C2 (en)1991-07-081993-11-11Deutsches Krebsforsch Phagemid for screening antibodies
ES2197145T3 (en)1991-08-202004-01-01The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services TRANSFER OF GENES MEDIATED BY ADENOVIRUS TO GASTROINTESTINAL.
ES2136092T3 (en)1991-09-231999-11-16Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
WO1993010218A1 (en)1991-11-141993-05-27The United States Government As Represented By The Secretary Of The Department Of Health And Human ServicesVectors including foreign genes and negative selective markers
GB9125623D0 (en)1991-12-021992-01-29Dynal AsCell modification
EP0552108B1 (en)1992-01-171999-11-10Lakowicz, Joseph R.Energy transfer phase-modulation fluoro-immunoassay
FR2688514A1 (en)1992-03-161993-09-17Centre Nat Rech ScientDefective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
US5733743A (en)1992-03-241998-03-31Cambridge Antibody Technology LimitedMethods for producing members of specific binding pairs
EP0650370A4 (en)1992-06-081995-11-22Univ California METHODS AND COMPOSITIONS FOR TARGETING SPECIFIC TISSUES.
CA2137361A1 (en)1992-06-101993-12-23W. French AndersonVector particles resistant to inactivation by human serum
SE9201984D0 (en)1992-06-291992-06-29Pharmacia Biosensor Ab IMPROVEMENT IN OPTICAL ASSAYS
GB2269175A (en)1992-07-311994-02-02Imperial CollegeRetroviral vectors
JPH08503855A (en)1992-12-031996-04-30ジェンザイム・コーポレイション Gene therapy for cystic fibrosis
US5981568A (en)1993-01-281999-11-09Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cells
ATE227979T1 (en)1993-04-222002-12-15Skyepharma Inc MULTIVESICULAR LIPOSOMES WITH ENCAPSULATED CYCLODEXTRIN AND PHARMACOLOGICALLY ACTIVE COMPOUNDS AND METHOD FOR THE USE THEREOF
EP0705344B8 (en)1993-06-242006-05-10Advec Inc.Adenovirus vectors for gene therapy
ATE440957T1 (en)1993-09-152009-09-15Novartis Vaccines & Diagnostic RECOMBINANT ALPHAVIRUS VECTORS
US6015686A (en)1993-09-152000-01-18Chiron Viagene, Inc.Eukaryotic layered vector initiation systems
EP1637608B1 (en)1993-10-252009-07-22CANJI, Inc.Recombinant adenoviral vector and methods of use
RO116341B1 (en)1993-11-162001-01-30Depotech Corp La JoliaMultivesicle liposome and process for producing the same
CA2158977A1 (en)1994-05-091995-11-10James G. RespessRetroviral vectors having a reduced recombination rate
AU4594996A (en)1994-11-301996-06-19Chiron Viagene, Inc.Recombinant alphavirus vectors
US6265150B1 (en)1995-06-072001-07-24Becton Dickinson & CompanyPhage antibodies
EP0953052B1 (en)1996-05-062009-03-04Oxford BioMedica (UK) LimitedCrossless retroviral vectors
ES2268763T3 (en)1997-01-212007-03-16The General Hospital Corporation SELECTION OF PROTEINS USING ARN-PROTEIN FUSIONS.
GB9809951D0 (en)1998-05-081998-07-08Univ Cambridge TechBinding molecules
CA2364484A1 (en)1999-03-092000-09-14University Of Southern CaliforniaMethod of promoting myocyte proliferation and myocardial tissue repair
CA2427523A1 (en)2000-11-012003-04-30Galpharma Co., Ltd.Predicting agent for metastasis
JP4578098B2 (en)2001-10-012010-11-10ダイアックス、コープ Multi-chain eukaryotic display vectors and their use
KR20050103474A (en)*2003-01-242005-10-31가르파마 컴퍼니 리미티드Drugs containing galectin 9
JP2004244411A (en)*2003-01-242004-09-02Galpharma Co LtdMedicament containing galectin-9
JP5021309B2 (en)2003-10-162012-09-05ステファン ジョン ラルフ Immunomodulatory compositions and methods of use thereof
KR20070107687A (en)2004-12-312007-11-07제넨테크, 인크. Polypeptides that bind to JR3, and uses thereof
US20070237764A1 (en)2005-12-022007-10-11Genentech, Inc.Binding polypeptides with restricted diversity sequences
JP5523345B2 (en)2008-01-182014-06-18ジェネンテック, インコーポレイテッド Methods and compositions targeting K63-linked polyubiquitin
ES2337224B1 (en)2008-06-112011-02-17Consejo Superior De Investigaciones Cientificas (Csic) (40%) ANTI-DECTIN-1 HUMAN ANTIBODY, PRODUCER HYBRIDOMA OF SUCH ANTIBODY AND ITS APPLICATIONS.
EP2310526A4 (en)2008-07-182011-11-02Oragenics IncCompositions for the detection and treatment of colorectal cancer
JP2013532153A (en)2010-06-182013-08-15ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Bispecific antibodies against TIM-3 and PD-1 for immunotherapy against chronic immune disease
MX346500B (en)2010-11-102017-03-22Genentech Inc *Methods and compositions for neural disease immunotherapy.
KR20130103587A (en)2010-12-092013-09-23가르파마 컴퍼니 리미티드Galectin 9-secreting cell, and production method and use of the same
US20140234320A1 (en)2011-06-202014-08-21La Jolla Institute For Allergy And ImmunologyModulators of 4-1bb and immune responses
WO2013056352A1 (en)*2011-10-192013-04-25University Health NetworkAntibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
US20140378531A1 (en)2012-02-012014-12-25New York UniversityInhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
US10966998B2 (en)2013-09-052021-04-06The Johns Hopkins UniversityCancer therapy via a combination of epigenetic modulation and immune modulation
JP2017518737A (en)2014-04-212017-07-13ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Anti-pSYK antibody molecules and their use for SYK targeted therapeutics
FR3021970B1 (en)*2014-06-062018-01-26Universite Sciences Technologies Lille ANTIBODY AGAINST GALECTIN 9 AND INHIBITOR OF THE SUPPRESSIVE ACTIVITY OF T REGULATORY LYMPHOCYTES
CN106999548A (en)2014-07-142017-08-01昆士兰医学研究所理事会 Galectin immunotherapy
CN107001466B (en)2014-09-162021-10-26依奈特制药公司Neutralization of inhibitory pathways in lymphocytes
WO2016061504A2 (en)*2014-10-172016-04-21The University Of ChicagoRecombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
US10837966B2 (en)2014-11-042020-11-17Dana-Farber Cancer Institute, Inc.Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
US20160209425A1 (en)2015-01-162016-07-21New York UniversityUse of dectin-1 activators for treatment of liver disorders
US10294294B2 (en)2015-09-102019-05-21Albert Einstein College Of MedicineSynthetic antibodies to BAX and uses thereof
US20190292259A1 (en)2016-05-242019-09-26Inserm (Institut National De La Sante Et De La Recherche Medicale)Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
US20180044422A1 (en)2016-07-292018-02-15New York UniversityTreating solid tumor by targeting dectin-1 signaling
CA3034105A1 (en)2016-09-232018-03-29Csl LimitedCoagulation factor binding proteins and uses thereof
PT3625263T (en)2017-10-272025-06-20Pure Tech Lyt IncAnti-galectin-9 antibodies and uses thereof
WO2020014465A1 (en)2018-07-112020-01-16Arrys Therapeutics, Inc.Polymorphic compounds and uses thereof
CA3134942A1 (en)2019-03-252020-10-01New York UniversityAnti-galectin-9 antibodies and uses thereof
JP7581238B2 (en)2019-05-012024-11-12ニューヨーク・ユニバーシティ Anti-galectin 9 antibodies and uses thereof

Also Published As

Publication numberPublication date
AU2018355588B2 (en)2020-10-15
US20190127472A1 (en)2019-05-02
JP7523084B2 (en)2024-07-26
WO2019084553A1 (en)2019-05-02
JP2023116789A (en)2023-08-22
EP3625263A4 (en)2021-05-05
IL274152A (en)2020-06-30
EP3625263B8 (en)2025-05-28
JP7307443B2 (en)2023-07-12
US20220340666A1 (en)2022-10-27
KR102162129B9 (en)2023-02-08
IL280648B1 (en)2024-06-01
NZ764590A (en)2020-12-18
SG11202003652QA (en)2020-05-28
US20190256604A1 (en)2019-08-22
US10450374B2 (en)2019-10-22
US11414492B2 (en)2022-08-16
AU2020294364A1 (en)2021-02-18
AU2018355588C1 (en)2023-04-27
JP6873445B2 (en)2021-05-19
US20200010551A1 (en)2020-01-09
KR102162129B1 (en)2020-10-06
IL312910A (en)2024-07-01
US20220332830A1 (en)2022-10-20
KR20200064150A (en)2020-06-05
EP3625263B1 (en)2025-04-09
ZA202002246B (en)2025-04-30
CN111511765A (en)2020-08-07
IL280648A (en)2021-03-25
CN111511765B (en)2022-05-27
ZA202102905B (en)2023-04-26
JP2024133590A (en)2024-10-02
JP2022116325A (en)2022-08-09
CA3080120C (en)2023-11-21
AU2020294364B2 (en)2023-09-21
DK3625263T3 (en)2025-06-30
EP3625263A1 (en)2020-03-25
JP2021153585A (en)2021-10-07
US10344091B2 (en)2019-07-09
AU2023285898A1 (en)2024-01-18
US11629191B2 (en)2023-04-18
JP2021501120A (en)2021-01-14
CN115261392A (en)2022-11-01
CN115261392B (en)2025-05-13
AU2018355588A1 (en)2020-06-11
ZA202303412B (en)2024-09-25
ES3032734T3 (en)2025-07-24
IL274152B (en)2021-02-28
CA3080120A1 (en)2019-05-02
IL280648B2 (en)2024-10-01
JP7092317B2 (en)2022-06-28
EP4597112A2 (en)2025-08-06

Similar Documents

PublicationPublication DateTitle
IL290842A (en)Anti-cd73 antibodies and uses thereof
ZA202102905B (en)Anti-galectin-9 antibodies and uses thereof
ZA202101318B (en)Anti-phf-tau antibodies and uses thereof
IL271477A (en)Anti-cd166 antibodies and uses thereof
IL268734A (en)Anti-lag-3 antibodies and uses thereof
IL276950A (en)Anti-cd73 antibodies and uses thereof
IL266738A (en)Novel antibodies and uses thereof
IL268206A (en)Bcma-targeting antibody and use thereof
IL264970A (en)Anti-tim-3 antibodies and use thereof
IL269134A (en)Anti-par2 antibodies and uses thereof
SG11201808632YA (en)Anti-pacap antibodies and uses thereof
EP3541840C0 (en)Anti-hla-g antibodies and use thereof
ZA201901935B (en)Anti-il-33 antibodies and uses thereof
IL273157A (en)Axl-specific antibodies and uses thereof
IL272476A (en)Anti-apelin antibodies and uses thereof
IL280321A (en)Anti-cxcr2 antibodies and uses thereof
IL277075A (en)Anti-phf-tau antibodies and uses thereof
IL266082A (en)Anti-chikv antibodies and uses thereof
IL266049A (en)Anti-o1 antibodies and uses thereof
IL264417A (en)Anti-o2 antibodies and uses thereof
IL274202A (en)Anti-glyco-muc1 antibodies and their uses
GB201712032D0 (en)Antibodies and uses thereof
SG11202003585VA (en)Anti-vista antibody and use thereof
IL276548A (en)Bcma-binding antibodies and uses thereof
ZA201906248B (en)Anti-ceacam1 antibody and use thereof

[8]ページ先頭

©2009-2025 Movatter.jp